With an eye on the FDA, Lex­i­con and Sanofi line up more pos­i­tive da­ta on di­a­betes drug

Lex­i­con Phar­ma­ceu­ti­cals $LXRX is beef­ing up the pos­i­tive da­ta it’s been ac­cu­mu­lat­ing for the SGLT1/SGLT2 in­hibitor so­tagliflozin as it preps ap­pli­ca­tions for Type 1 di­a­betes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER